Hitherto unseen survival in an ALK‐positive‐patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine. Issue 12 (7th November 2017)

• Record Type: Journal Article
• Authors: Risum, Signe; Knigge, Ulrich; Langer, Seppo W.
• Is Part Of: Clinical case reports. Volume 5:Issue 12(2017)
• Page Start: 2085
• Page End: 2087
• Publication Date: 2017-11-07
• Subjects: Ganglioneuroblastoma -- multimodal treatment -- stage 4 -- survival; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.1262
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment. Abstract : Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years. We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.